TR199901000T2 - �entik. - Google Patents

�entik.

Info

Publication number
TR199901000T2
TR199901000T2 TR1999/01000T TR9901000T TR199901000T2 TR 199901000 T2 TR199901000 T2 TR 199901000T2 TR 1999/01000 T TR1999/01000 T TR 1999/01000T TR 9901000 T TR9901000 T TR 9901000T TR 199901000 T2 TR199901000 T2 TR 199901000T2
Authority
TR
Turkey
Prior art keywords
cell
interactions
compounds
relates
allergies
Prior art date
Application number
TR1999/01000T
Other languages
English (en)
Turkish (tr)
Inventor
Robert Lamb Jonathan
Jane Dallman Margaret
Francis Hoyne Gerald
Original Assignee
Lorantis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9623236.8A external-priority patent/GB9623236D0/en
Priority claimed from GBGB9715674.9A external-priority patent/GB9715674D0/en
Priority claimed from GBGB9719350.2A external-priority patent/GB9719350D0/en
Application filed by Lorantis Limited filed Critical Lorantis Limited
Publication of TR199901000T2 publication Critical patent/TR199901000T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
TR1999/01000T 1996-11-07 1997-11-06 �entik. TR199901000T2 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9623236.8A GB9623236D0 (en) 1996-11-07 1996-11-07 Notch
GBGB9715674.9A GB9715674D0 (en) 1997-07-24 1997-07-24 Notch
GBGB9719350.2A GB9719350D0 (en) 1997-09-11 1997-09-11 Notch

Publications (1)

Publication Number Publication Date
TR199901000T2 true TR199901000T2 (xx) 1999-07-21

Family

ID=27268574

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01000T TR199901000T2 (xx) 1996-11-07 1997-11-06 �entik.

Country Status (20)

Country Link
EP (2) EP0942998B1 (enExample)
JP (1) JP4339406B2 (enExample)
KR (1) KR100393234B1 (enExample)
CN (2) CN1160371C (enExample)
AT (1) ATE299184T1 (enExample)
AU (1) AU736361B2 (enExample)
BG (1) BG103444A (enExample)
CA (1) CA2271248C (enExample)
CZ (1) CZ295997B6 (enExample)
DE (1) DE69733695T2 (enExample)
ES (1) ES2243986T3 (enExample)
GB (2) GB2353094B (enExample)
GE (1) GEP20043390B (enExample)
IL (1) IL129531A0 (enExample)
NO (1) NO992196L (enExample)
NZ (1) NZ335549A (enExample)
PL (1) PL333302A1 (enExample)
RO (1) RO120850B1 (enExample)
TR (1) TR199901000T2 (enExample)
WO (1) WO1998020142A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334953T3 (es) 1995-06-28 2010-03-17 Imperial Cancer Research Technology Limited Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos.
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB9824045D0 (en) * 1998-11-03 1998-12-30 European Molecular Biology Lab Embl Regulator protein
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB0019242D0 (en) * 2000-08-04 2000-09-27 Lorantis Ltd Assay
CA2422538C (en) * 2000-09-22 2012-06-19 Genentech, Inc. Notch receptor agonists and uses
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
CA2454937A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
CA2475288C (en) * 2002-02-06 2014-09-02 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
WO2003087159A2 (en) * 2002-04-05 2003-10-23 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
EP1525221A1 (en) * 2002-08-03 2005-04-27 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
GB0218879D0 (en) * 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
GB0220658D0 (en) * 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
EP1549347A1 (en) * 2002-10-09 2005-07-06 Lorantis Limited Modulation of immune function
WO2004060262A2 (en) * 2003-01-07 2004-07-22 Lorantis Limited Modulators of notch signalling for use in immunotherpapy
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
WO2004064863A1 (en) * 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
GB0303663D0 (en) * 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
WO2004083372A2 (en) * 2003-03-21 2004-09-30 Lorantis Limited Modulators of the notch signaling pathway immobilized on particles for modifying immune responses
ATE474593T1 (de) * 2003-03-21 2010-08-15 Celldex Therapeutics Ltd Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP5560270B2 (ja) 2008-07-08 2014-07-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ結合剤およびアンタゴニストならびにその使用方法
US9475855B2 (en) * 2008-08-22 2016-10-25 The Trustees Of Columbia University In The City Of New York Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
WO2010091679A2 (de) * 2009-02-16 2010-08-19 Deutsches Rheuma-Forschungszentrum Berlin Verwendung von notch-regulatoren zur modulation der immunantwort durch induktion/suppression von interleukin-22
CN105131112A (zh) 2009-08-29 2015-12-09 Abbvie公司 治疗用dll4结合蛋白
AU2011223919B2 (en) 2010-03-02 2015-03-19 Abbvie Inc. Therapeutic DLL4 binding proteins
JP5932970B2 (ja) * 2011-04-06 2016-06-08 サンバイオ，インコーポレイティド 末梢免疫機能を調節するための方法及び組成物
WO2013074596A1 (en) * 2011-11-16 2013-05-23 Oncomed Pharmaceuticals, Inc. Human notch receptor mutations and their use
US20150140043A1 (en) * 2012-05-10 2015-05-21 Institut National De La Sante De La Recherche Medical (Inserm) Immunomodulatory methods using notch agonists
KR101573650B1 (ko) 2015-02-04 2015-12-01 성균관대학교산학협력단 Hcmv 바이러스 복제 억제용 조성물
EP3844266A1 (en) * 2018-08-28 2021-07-07 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
AU689214B2 (en) * 1994-02-01 1998-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fusion proteins that include antibody and nonantibody portions
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide

Also Published As

Publication number Publication date
GB2335194A (en) 1999-09-15
CZ295997B6 (cs) 2005-12-14
IL129531A0 (en) 2000-02-29
CA2271248A1 (en) 1998-05-14
GB9910276D0 (en) 1999-06-30
GB2335194B (en) 2001-04-25
EP0942998B1 (en) 2005-07-06
DE69733695D1 (de) 2005-08-11
NZ335549A (en) 2001-07-27
ATE299184T1 (de) 2005-07-15
CN1524583A (zh) 2004-09-01
CN1242802A (zh) 2000-01-26
AU736361B2 (en) 2001-07-26
RO120850B1 (ro) 2006-08-30
WO1998020142A1 (en) 1998-05-14
ES2243986T3 (es) 2005-12-01
KR20000053146A (ko) 2000-08-25
CZ163999A3 (cs) 1999-10-13
NO992196L (no) 1999-07-05
GB0023691D0 (en) 2000-11-08
JP2001504331A (ja) 2001-04-03
PL333302A1 (en) 1999-11-22
JP4339406B2 (ja) 2009-10-07
AU4876597A (en) 1998-05-29
KR100393234B1 (ko) 2003-07-31
DE69733695T2 (de) 2006-05-18
NO992196D0 (no) 1999-05-05
EP0942998A1 (en) 1999-09-22
CA2271248C (en) 2009-08-11
GB2353094A (en) 2001-02-14
GEP20043390B (en) 2003-11-10
EP1616958A2 (en) 2006-01-18
GB2353094B (en) 2001-06-13
CN1160371C (zh) 2004-08-04
BG103444A (en) 2000-06-30
EP1616958A3 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
TR199901000T2 (xx) �entik.
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DE69919754D1 (de) Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
TR200002284T2 (tr) Mage ailesinden tümör ile ilgili tümör türevleri
TR200001544T2 (tr) Yeni bileşikler.
AU3777989A (en) Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
DE69334148D1 (de) HIV-Peptide
TR199800679T2 (xx) Kiral metil fenil oksazolidinon.
ATE544470T1 (de) Immuntherapeutische methoden und zusammensetzungen
DE50201191D1 (de) Filteranordnung
TR199800445A2 (xx) cdc25B geni y�kselticisi, haz�rlan��� ve kullan�m�.
TR200002987T2 (tr) Optik özelliklere sahip olan poli (Alkilen Arilatlar).
FR2771751B1 (fr) Erythrovirus et ses applications
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
ATE428500T1 (de) Kunststoff-geträgerte phosphorliganden verwendbar in der katalyse
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
DE69836485D1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
AU6722498A (en) Disubstituted biphenyloxazolines
DE50013908D1 (de) Zytotoxisches t-zellepitop des papillomavirus l1-proteins und seine verwendung in diagnostik und therapie
ZA98587B (en) A novel antigen from P. aeruginosa, and its use in medicine.